Targeted Modulation of the Death Receptor as a Therapeutic Strategy for Glioma

死亡受体的靶向调节作为神经胶质瘤的治疗策略

基本信息

批准号：
8526585
负责人：
JAY FITZGERALD DORSEY
金额：
$ 18.92万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-30 至 2016-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8526585
关键词：
Abramson Cancer Center at the University of Pennsylvania Accounting Achievement Adult Agonist Animals Apoptosis Apoptotic Area Binding Biochemical Biological Biological Assay Board Certification Brain Neoplasms Cancer Center Caspase Cell Death Cell Line Cell Surface Receptors Cells Cellular Assay Cellular Stress Cellular biology Center for Translational Science Activities Cessation of life Characteristics Clinic Clinical Commit DNA Damage Data Development Diagnosis Disease Embryo Ensure Environment Evaluation Exhibits FDA approved Funding Genetic Glioblastoma Glioma Goals HIV Protease Inhibitors Human Image In Vitro Journals Lead Ligands Luciferases Malignant - descriptor Malignant Glioma Malignant Neoplasms Malignant neoplasm of brain Measures Mediating Medicine Mentors Mentorship Modeling Molecular Biology Molecular Target Monoclonal Antibodies Mus Nature Nelfinavir Operative Surgical Procedures Outcome Pathway interactions Pennsylvania Phase Phase I Clinical Trials Physicians Positioning Attribute Primary Brain Neoplasms Process Public Health Radiation Radiation Oncology Radiobiology Recombinants Reporter Research Research Personnel Research Project Grants Residencies Resources Schedule Scientist Signal Transduction Stress System TNFRSF10A gene TNFRSF10B gene TNFSF10 gene Testing The Wistar Institute Therapeutic Toxic effect Training Training Programs Transcriptional Activation Translating Tumor Necrosis Factor-alpha United States Universities Up-Regulation Validation Xenograft Model Xenograft procedure Zebrafish arm base bench to bedside cancer cell cancer therapy career career development chemoradiation chemotherapy clinically relevant design effective therapy efficacy testing expectation experience high throughput screening improved in vivo innovation meetings model development molecular imaging mouse model multimodality novel novel therapeutic intervention novel therapeutics pre-clinical professor programs proton therapy receptor research and development response safety testing skills small molecule small molecule libraries temozolomide treatment strategy tumor tumor growth tumorigenesis

项目摘要

DESCRIPTION (provided by applicant): This proposal describes a 5 year training program for the candidate's development as a Physician-Scientist and successful Independent Investigator. The candidate has completed Residency training in Radiation Oncology at the University of Pennsylvania and has passed his Radiation Oncology Board-Certification exams. He will now expand his scientific skills through a customized integration of institutional resources and mentored experiences. The candidate has a background in cell and molecular biology, but will greatly benefit from additional training in radiation biology, radiation oncology, molecular imaging, high-throughput screening, and experimental therapeutics. The University of Pennsylvania and the Department of Radiation Oncology have committed to fully support the proposed career development program and provide an ideal setting for training Physician-Scientists by acquiring and maintaining outstanding resources and nurturing a collaborative environment. Such an environment maximizes the potential for the candidate to construct a successful independently-funded academic career. The project described therefore takes advantage of the exceptional resources available at the Abramson Cancer Center and the University of Pennsylvania. Co-leaders of the Abramson Cancer Center's Radiation Biology & Imaging Program, Dr. Constantinos Koumenis, Associate Professor of Radiation Oncology and Dr. Stephen M. Hahn, Henry K. Pancoast Professor and Chair of Radiation Oncology will mentor the candidate's scientific and career development. Together, Drs. Koumenis and Hahn have formalized a research plan with a career development strategy augmented by a strong formal program that includes regular lab meetings, seminars, journal clubs and didactic training as well as a process of regularly scheduled review to ensure progress. The proposed research will focus on delivering molecular targeted therapy for Glioblastoma Multiforme (GBM) via the novel strategic integration of ER stress and the extrinsic pathway of apoptosis. Despite the recently demonstrated efficacy of temozolomide (Temodar) in treating glioblastoma multiforme (GBM), it remains an incurable and devastating disease. New therapeutic approaches are desperately needed. The candidate has identified a novel mechanistic model of therapy that integrates the ER stress and death receptor pathways in human GBM cells to induce apoptosis. Effective pre-clinical validation of this integrated therapeutic strategy could serve as a model for development of ER stress/apoptosis-based targeted therapy against cancer in general. This project aligns well with the immediate career goal of applying mechanistic and high-throughput screening approaches to identify novel targets for cancer therapy, and the long-term career goal of translating these findings into effective targeted therapy for high-grade brain tumors. The mentorship of Drs. Constantinos Koumenis and Stephen Hahn, the unique resources and collaborative nature of the Abramson Cancer Center/University of Pennsylvania, and the translational clinical activities in the Roberts Proton Therapy Center/Perelman Center for Advanced Medicine/Translational Research Center together provide an exceptional environment to support the successful execution of the research project and the career development of the candidate. Furthermore, the program incorporates unique external scientific resources and expertise from the Wistar Institute and Johns Hopkins University to enhance the candidate's research and career development. Through the completion of the program described, the candidate will proceed to full independence with the expectation of successful achievement of R01 funding within five years.

描述（由申请人提供）：该提案描述了为候选人开发的5年培训计划，作为医师科学家和成功的独立研究员。候选人已完成宾夕法尼亚大学放射肿瘤学的居住培训，并通过了他的放射肿瘤学董事会认证考试。现在，他将通过定制的机构资源和指导经验来扩展他的科学技能。候选人具有细胞和分子生物学的背景，但将从辐射生物学，辐射肿瘤学，分子成像，高通量筛选和实验治疗学方面的额外培训中受益匪浅。宾夕法尼亚大学和放射线肿瘤学系致力于充分支持拟议的职业发展计划，并通过获取和维护出色的资源并培养协作环境，为培训医师科学家提供理想的环境。这样的环境最大程度地提高了候选人建立成功独立资助的学术生涯的潜力。因此，所描述的项目利用了艾布拉姆森癌症中心和宾夕法尼亚大学可用的特殊资源。艾布拉姆森癌症中心的辐射生物学与成像计划的共同领导者，放射肿瘤学副教授康斯坦丁斯·库梅尼斯博士和亨利·K·帕科斯特（Henry K. Pancoast 。在一起，博士。 Koumenis和Hahn已通过强大的正式计划增强了一项研究计划，其中包括定期实验室会议，研讨会，期刊俱乐部和教学培训，以及定期安排的审查过程以确保进步。拟议的研究将着重于通过ER应力的新战略整合和细胞凋亡的外部途径来提供分子靶向多种形式（GBM）的分子靶向疗法。尽管最近证明了替莫唑胺（Temodar）在治疗多形胶质母细胞瘤（GBM）方面的功效，但它仍然是一种无法治愈且破坏性的疾病。迫切需要新的治疗方法。候选人已经确定了一种新型的治疗机械模型，该模型将人类GBM细胞中的ER应力和死亡受体途径整合起来诱导凋亡。对这种综合治疗策略的有效临床前验证可以作为开发基于ER应激/凋亡的靶向治疗对癌症的模型。该项目与应用机械和高通量筛查方法的直接职业目标相吻合，以识别癌症治疗的新目标，以及将这些发现转化为有效的高级脑肿瘤的有效靶向治疗的长期职业目标。博士的指导。康斯坦丁诺斯·库梅尼斯（Constantinos Koumenis）和斯蒂芬·哈恩（Stephen Hahn），艾布拉姆森癌症中心/宾夕法尼亚大学的独特资源和协作性质，以及罗伯茨质子治疗中心/佩雷尔曼高级医学/翻译研究中心的转化临床活动，为支持提供了一个非凡的环境研究项目的成功执行和候选人的职业发展。此外，该计划结合了Wistar Institute和Johns Hopkins大学的独特外部科学资源和专业知识，以增强候选人的研究和职业发展。通过完成所描述的计划，候选人将在五年内成功实现R01资金，继续完全独立。